Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating
from and ultimately sustained by a rare population of BCR-ABL+ cells with multilineage stem
cell properties. Imatinib, the most successful of molecular targeted therapies, has
revolutionized treatment of patients with CML. Despite this achievement, CML is often not
curable, largely due to the innate insensitivity of CML stem cells, particularly when in a
quiescent state. This failure of not only imatinib but also the second-generation tyrosine …